Member Info for AquaeSulis01

But the comment "Trading continues in line with expectations in all Group entities for the full year to June 2025, reflecting strong BTS revenues since acquisition, elements of seasonality in the Dermatonics business, and strong sales in the first few months of calendar year 2025." means revenue must still be on track to hit the projections for the Full Year

Short term it is Toyin as nobody believes SOH is looking to sell more than he has to at current sp whilst Macq Bank have no such compunction

All pretty irrelevant whilst Macq Bank are sat on a further 2,099,244 warrants which they can exercise just over 20p (and probably already have) at their leisure now

Bit more info here. makes you wonder why they are not presenting at the In-Cosmetic 2025 launch?

https://www.crodabeauty.com/en-gb/resources/webinars/biotechnologies-35-years-of-expertise

I know like you Lord where most of the money has been spaffed so the comment "New technologies such as SweetBiotix do not come cheap either with R&D etc (look at SBTX investment in Skinbiotix), likely a few £m has been spent on that alone. Sweetbiotix could be its own company and as big as if not much bigger than SBTX." did need addressing especially as sweetbiotix has been around since 2018 and the deal with the partners involved taking it forward at their own expense

Investors given a large dividend, are you serious Letitrun? The sp for the Combined OPTI Company was 40p immediately prior to splitting out PBX and awarding shareholders with a locked in share on an illiquid exchange. The only person to reap a large dividend is the CEO's mate "ProBiotix is pleased to announce that Holdingselskabet af 29. Juni 2010 Aps, the family office vehicle of successful Denmark based investor and entrepreneur, Frederik Bruhn-Petersen, has subscribed for 36,500,000 new ordinary shares of 0.05p each in the Company ("Ordinary Shares", "New Ordinary Shares") at a subscription price of 3.36p per share, raising £1,226,400 (before expenses)".

As for using SBTX sales to fund R&D, Opti has spent a grand total of £68k in 2022 and £48K in 2023 and has likely wasted far more fighting the award and appointment of Holdingselskabet

Protein based Bacteria poop in layman's terms

First, thanks for posting the Podcast link mol.

Lord, regarding speculation that horse bolted when SOH named these Companies amongst others himself I would suggest.

Worth noting the wording of both sweetbiotix partner agreements;

" A manufacturing agreement signed with a US partner in September 2020. They are paying OptiBiotix a six figure annual milestone in H2 every year during scale up plus a six figure launch milestone payment with royalties of 5% on all sales and a further 5% on sales to 11 named companies (Kelloggs, Nestle, Coca Cola , Firmenich, Tereos, Cargill, Arla ,Tate and Lyle, Agropur, Givaudan, Tata) reflecting the development work ongoing with these partners before we signed the agreement.

2. An agreement was signed with Firmenich in July 2022 to optimise scale up and development of another type of SweetBiotix®. They will pay OptiBiotix a six figure payment per market approval (USA/Europe/Asia) plus royalties and additional milestones on sales. As previously disclosed, Firmenich are one of the world leaders in taste and the world's largest stevia supplier. Their turnover is around £3.6bn per year which has risen to US $11.4bn annual turnover following their merger with DSM, and are now known as DSM Firmenich. They are experts in their field and chose SweetBiotix® after an 18 month due diligence process. This agreement with one of the leaders in the field after extensive due diligence of the science, taste, and intellectual property, is a substantial validation of the SweetBiotix® science and commercial potential."

Note the additional royalty payments for certain named Companies was associated with the US Partner who i believe was dealing with sweetbiotix derived from Mogroside V (Monk Fruit). My own theory for SOH negotiating a different agreement with DSM/Firmenich based on the lack of mention anymore of the US Partner is that the agreement with the US Partner has lapsed as their scale-up failed to faithfully replicate the lab based sweetbiotix methodology which has impacted the structure. Consequently, the focus is now on DSM/Firmenich supplying the named Companies with Stevia based sweetbiotix products and as SOH has already done a lot of the engagement work with those Customers he now wants a bigger slice of the pie than originally negotiated without them in play

Agree difficult to make sense of the percentage increases on small numbers Friedman. What we can deduce regarding the Dr Morepen sales is from the pre-launch RNS we were told "OptiBiotix Health India

This area of the business has seen a material transformation in outlook with the announcement of the agreement with Morepen (announced on 13 March 2024) to sell products containing SlimBiome® under the Dr Morepen brand. This is an established, well known, and trusted brand in the Indian market and represents a material step forward for the Company's products in the Indian market. OptiBiotix will receive revenue for both the ingredient and final product sales with the first order received in May 2024 of over £175K for delivery and launch in Q3 2024. The initial launch planned for Q3 2024 will involve five products with subsequent launches later in the year and at the start of 2025. " hence as they have now re-ordered more slimbiome and products at least £175K has been sold in circa 3 months which is a decent start

Bazza what is the point of an Inv Meets just before the EOY Financials are issued, there will be a much more informative one to follow?

And other health benefits

"Microplastics (MP) contamination in food and water poses significant health risks. While microbes that form biofilm show potential for removing MP from the environment, no methods currently exist to eliminate these non-degradable MP from the human body. In this study, we propose using probiotics to adsorb and remove ingested MP within the gut. We conducted a comprehensive evaluation of 784 bacterial strains to assess their ability to adsorb 0.1 μm polystyrene particles using a high-throughput screening method. Among the tested strains, Lacticaseibacillus paracasei DT66 and Lactiplantibacillus plantarum DT88 exhibited optimal adsorption in vitro and were effective across various MP types. In an animal model, mice treated with these probiotics demonstrated a 34% increase in PS excretion rates and a 67% reduction in residual polystyrene (PS) particles within the intestine. Additionally, administration of Lactiplantibacillus plantarum DT88 mitigated PS-induced intestinal inflammation. Together, our findings demonstrate a novel probiotic strategy for addressing MP-associated health risks, emphasizing the potential of strain-specific probiotics to remove MP from the gut environment."

https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1522794/full

Because Bonker "Refreshed contractual confirmations for process plant and mining services are in train, so that signings can occur with up-to-date fixed-price and other relevant components;" means that the sale of Saudi Assets is required to pay for the additional costs at today's prices (package value based on costs set over 2 years ago).

Not forgetting 2.3M warrants for Maq bank now potentially in play and they most certainly will sell

TW I have a Customer hat on when I comment on the Porridge situation and as there is no equivalent healthy and enjoyable alternative out there and I have the porridge daily there is no upside.

Patents take on average 14 weeks from date of filing to publish on US Patent database. patents were scheduled to be filed end Nov hence Thurs 06th Mar earliest likely to appear. No news until patents are published to guard against spoiling patents from Competitors. The products Croda are presenting at In-Cosmetics have already changed at least 3 times in recent weeks so can be changed at a drop of a hat. The launch is happening, Croda experienced in maximising impact and publicity will be timed to the minute

Can see H&B dropping slimexpert altogether so have quickly bought another 9 boxes of the Golder Syrup porridge whilst still in stock. the shots are the equivalent of slim medical and are not the best in terms of flavour s no surprise to see them being sold off, add to that the 3 * per day recommended intake and the extra glass of water to help the slimbiome expand in the stomach and you can see why it has failed to take off. The Lemonade powder added to the extra amount of water so that a second glass of pure water does not have to follow it is a much better idea and the recommended intake is just once per day before the main meal. The pity is if you combined the Dr Morepen app with the slimexpert Golden Syrup breakfast porridge and the lemonade, alongside normal meals, you would have a real winner that would soon become a normal routine for many

Molatovkid, it has been imminent too many times buy these as though they are going out fashion. Unless a RNS drops by cop today to confirm the ratification by the Ethiopian Parliament of AFC then this will be yet another milestone that has become a millstone around Harry's neck.

Quick observation and question; the cost of the Tulu Kapi Mining operations were costed at $320M in Nov 2022

"21st Nov 2022 RNS

KEFI (AIM: KEFI), the gold exploration and development company with projects in the Federal Democratic Republic of Ethiopia and the Kingdom of Saudi Arabia, is pleased to announce that the updated US$320 million Tulu Kapi Gold Project ("Tulu Kapi" or the "Project") costings and finance plan has now been agreed by all the Tulu Kapi syndicate lead contractors, investors and lenders. It is currently being processed for final reviews and entry into definitive documentation to be signed as soon as possible, with the expectation to achieve this next month."

The 7th Jan 2025 Presentation still had the cost of the Financial Package at $320M despite inflation upping the cost of material and labour in the interim; from the Corporate Snapshot Slide "Project Financing almost Complete: ▪ Banks debt package increased to $240M of total $320M package ▪ Equity risk capital $80M mainly from Equity Risk Note and Shares in Subs"

The 3rd -4th Feb 2025 Presentation Slide included a contribution from the sale of the Saudi Assets of $20M as the non-bank contribution is shown up from $80M to $100M dollars "▪ Project Financing almost Complete: ▪ Terms agreed for Banks debt package increase to $240M of total $320M package ▪ Equity risk capital $100M from issue of Shares and EthioBonnds from Subsidiaries plus proceeds of sale of minority shareholding on GMCO

Note *The metrics for Tulu Kapi updated from November 2024 FX rate and for updated fees and charges by Senior Lenders. Otherwise unchanged from November 2024"

So even though the Total Cost figure of $320M has not been updated on the slide surely that is an error as $240M + $100M = $340M and hence the sale of the Saudi Assets is an essential part of the Tulu Kapi finance package to cover the increased costs or am I missing something?

All true re the handwashes etc but that falls to the Cleanbiotix Pillar which is some years away so can't get too enthused about it just yet with much bigger fish about to be landed just around the corner.

WIILG, from the original Commercial RNS announcement Nov 2019

"Under the terms of the agreement, SkinBioTherapeutics' proprietary SkinBiotix™ platform will be paired with Croda's expertise in the development and commercialisation of unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market. Sederma, part of Croda International, is a specialist in bioactive ingredients for the cosmetic industry, and will be responsible for the development, manufacturing and commercialisation of the SkinBiotix™ technology. As design and build of the active ingredient is carried out there will be concurrent testing in focussed application areas which will be detailed in further, additional agreements.

Any licensed products resulting from this agreement will be sold to Croda's global portfolio of Personal Care customers. SkinBioTherapeutics will be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership which will be subsequently agreed on successful development of the technology.

Sales and distribution rights are for the cosmetic sector alone, leaving SkinBioTherapeutics to focus on further applications of its technology in other sectors.

* Skincare actives have been scientifically proven to deliver their beneficial effects at a cellular level, providing a range of effects including to repair, rejuvenate, hydrate, protect and nourish in order to improve the quality of the skin.

Arnaud Fournial, Managing Director of Sederma, said:

"The SkinBiotix™ technology has a solid scientific foundation which attracted us in the first place. We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market. We look forward to a fully collaborative partnership with the SkinBioTherapeutics team and to seeing SkinBiotix™ being embraced by our global partners as a key ingredient across a variety of products to protect and rejuvenate skin."

https://www.lse.co.uk/rns/SBTX/commercial-agreement-9nkv8hwy6q1y6mk.html